Expert hematologist-oncologist Thomas G. Martin, MD, shares data from the IKEMA subgroup analysis in patients with relapsed multiple myeloma treated with isatuximab, carfilzomib, and dexamethasone.
Thomas Martin, MD, University of California San Francisco
Advertisement
Articles by Thomas Martin, MD, University of California San Francisco
Advertisement
Latest Updated Articles
Targeted Treatment Options in Multiple MyelomaAugust 10th 2020
The Future of Multiple MyelomaAugust 10th 2020
A Look at the ENDURANCE TrialAugust 10th 2020
Maintenance Therapy in Multiple MyelomaAugust 10th 2020
Treatment Options in Relapsed/Refractory Multiple MyelomaAugust 10th 2020
Trials in Relapsed/Refractory Multiple MyelomaAugust 10th 2020
Advertisement
Advertisement
Trending on OncLive
1
HERIZON-GEA-01 PD-L1 Subgroup Data Support Zanidatamab Combo as a New Frontline SOC in HER2+ GEA
2
Antibody-Drug Conjugates in Lung Cancer: The Tip of the Iceberg
3
Selinexor Plus Ruxolitinib Yields Superior Spleen Responses, OS Signal in JAK Inhibitor–Naïve Myelofibrosis
4
Retrospective Data Show Zanubrutinib May Less AFib Burden in Real-World CLL
5